Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MK-1045 |
| Trade Name | |
| Synonyms | MK 1045|MK1045|CN201|CN-201|CN 201 |
| Drug Descriptions |
MK-1045 is a humanized bispecific antibody targeting CD19 and CD3, which may lead to increased anti-tumor immune response (Blood (2025) 146 (Supplement 1): 3740). |
| DrugClasses | CD19 Antibody 23 CD3 Antibody 125 |
| CAS Registry Number | NA |
| NCIT ID | C192820 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| MK-1045 | MK-1045 | 0 | 2 |